AU - Ajay, Kumar AU - Garg, Ashish AU - Garg, Sweta AU - Bhatt, Shevtank AU - Mishra, Neeraj TI - Nanoparticle-based dry Powder Inhaler-Based Approach for Corona Virus Disease-2019 Treatment: An Update PT - REVI DP - 2020 Oct 1 TA - International Journal of Health & Allied Sciences PG - 322-328 VI - 9 IP - 4 4099- https://www.ijhas.in/article.asp?issn=2278-344X;year=2020;volume=9;issue=4;spage=322;epage=328;aulast=Ajay;type=0 4100- https://www.ijhas.in/article.asp?issn=2278-344X;year=2020;volume=9;issue=4;spage=322;epage=328;aulast=Ajay AB - Corona virus disease-2019 (COVID 19) is a respiratory disorder caused by bunches of serious respiratory disorders (i.e., coughing, fever, and breathing problems) like severe acute respiratory syndrome (SARS), and the 79% homology as well as gene sequences are basically similar to SARS-CoV, thus the name of COVID-19 also be distinguish as SARS-CoV-2 on January 7th. Nanoparticles may also improve drug pulmonary efficacy by enhancing residence time, as a consequence the efficient mucus complexation between mucin and nanoparticles caused increment the rate of permeation and tissue uptake and displayed sustainable release property. Advances in device technology have led to the development of more efficient delivery systems capable of delivering larger doses and finer particles into the lung. As more efficient pulmonary delivery devices and sophisticated formulations become available, physicians, and health professionals will have a choice of a wide variety of device and formulation combinations that will target-specific cells or regions of the lung, avoid the lung's clearance mechanisms and be retained within the lung for longer periods. Dry powder inhalers (DPIs) exhibit many unique advantages that have contributed to the incredible growth in the number of DPI pharmaceutical products. To improve the performance, there are a relatively large number of DPI devices available for different inhalable powder formulations. The present review different type of nanoaparticles and DPIs used for the treatment of COVID 19 infections.